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INFLUENZA AS A HEALTH PROBLEM OF SEA TRAVELLERS 
ANETA NITSCH-OSUCH 1 
ABSTRACT 
Traveling people may play an important role in spreading of influenza viruses in the 
word. The risk for exposure to influenza during travel depends on the time of year and 
destination, and the way of traveling (individual trip or organized excursion with a large 
group of people, especially coming from many different countries). Results of recent 
studies indicated that influenza may be the most frequent vaccine-preventable infectious 
disease with symptoms from respiratory tract. It is estimated that the attack rate of 
influenza in intercontinental travelers is 1%. 
The aim of the article is to describe current recommendations for travelers, 
especially see travelers (passengers and crew), concerning influenza prophylaxis, 
treatment and possible outbreak control. 
Guidelines for the prevention and control of influenza –like illness among 
passengers and crew members on cruise ships have also been described.  
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Influenza is an acute infectious disease caused by influenza virus A, B or C. The 
influenza virus belongs to Orthomyxoviridae and is spread by a droplet way. Influenza 
is a serious disease because of its possible impact on the health of individuals (severe 
complications, especially in patients from risk groups), and economic loss for 
individuals and the community [1].  
Influenza may spread as an epidemic or a pandemic disease which requires a good 
virological and epidemiological surveillance – especially nowadays when highly 
pathogenic A (H5N1) strain is typed as one of potential future pandemic viruses [2,3]. 
Traveling people may play an important role in spreading influenza viruses in the 
word [2,3]. The risk for exposure to influenza during travel depends on the season of the 
year, the destination, and the way of travelling (individual trip or organized excursion 
with a large group of people, especially if they are coming from many different 
countries). Results of recent studies indicated that influenza may be the most important 
vaccine-preventable infectious disease with symptoms from respiratory tract [4]. It is 
estimated that the attack rate of influenza in intercontinental travellers is 1% [5]. 
The aim of the article is to describe current recommendations for travellers, 
especially see travellers (passengers and crews of ships), concerning influenza 
prophylaxis, treatment and  outbreak control. 
GEOGRAPHICAL DISTRIBUTION 
Influenza distribution varies in the world varies [6-8]: 
• in the Northern Hemisphere epidemics tend to occur in winter months from 
November to March, mainly in January and February; 
• in Southern Hemisphere epidemics occur in from May to October, mainly in 
June and July; 
• in the tropics the disease is present at any time of the year, especially during the 
rainy season. 
Geographical and seasonal pattern of the spread of influenza defines 
recommendations for the time of vaccination of travellers. 
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GENERAL RECOMMENDATIONS FOR VACCINATIONS 
Vaccinations against influenza are recommended to [6-8]: 
• all travellers belonging to risk groups regarding complications (table 1); 
• if there are no medical contraindications – all travellers  who want to avoid the 
disease and its complications; 
• travellers from Northern Hemisphere going to Southern Hemisphere  from 
April to September, and those coming from Southern Hemisphere to Northern 
Hemisphere from November to March; 
• large groups of people (pilgrims, participants of cruises, especially long term 
cruises); 
• people travelling to the tropics (all the year). 
 
Table 1. Risk groups for whom annually vaccination against influenza is 
recommended [6]. 
 
Persons aged > 50 years 
Healthy children aged 0-59 months 
Children older than 6 months with chronic diseases of respiratory tract and 
cardiovascular system 
Children aged < 18 years chronically treated with aspirin 
Residents of nursing homes 
Individuals with chronic cardiopulmonary disorders 
Persons who require regular medical care for chronic metabolic, renal diseases or 
hemoglobinopathies 
Patients with immunosupression (including HIV) 
Pregnant women 
Health care workers 
Household contacts and out-of-home caregivers of children up to the age of 23 months  
 Household contacts of persons at high risk for complications of influenza 
 
The US Centers for Disease Control and Prevention recommend that: 
 
• travelers departing for the tropics at any time of the year or to the Southern 
Hemisphere from May to October should consider vaccination if they were not 
vaccinated the previous fall or winter; 
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• travelers who before departure receive the previous seasons vaccine should be 
vaccinated again when the next season’s vaccine becomes available [8]. 
The most recent vaccine available at home country may not cover all of the strains 
encountered by the traveller. If strains are known to be circulating in the destination 
country that are not covered by the available vaccine, the traveller should consider 
obtaining the appropriate vaccine after his or her arrival [8]. 
In adults protection begins roughly 2 weeks after vaccination and lasts 6 months or 
more. Two doses given at least 1 month apart is necessary to obtain a satisfactory 
antibody response in previously unvaccinated children under 9 years. Vaccinations 
should be planned at least two weeks before travel in adults and 6 weeks before travel in 
previously not vaccinated children aged less than 9 years [8]. 
Table 2. Comparison of live attenuated influenza vaccine (LAIV) with inactivated 
influenza vaccine (TIV) [6]. 
 TIV LAIV 
Route of administration intramuscular 
injection 
intranasal spray 
Approved age and risk groups aged > 6 months healthy persons 5-49 years 
Type of virus inactivated virus live attenuated virus 
Spacing with inactivated 
vaccines 
Anytime anytime 
Spacing with life vaccines any time prudent to space 4 weeks  
apart or give simultaneously 
Use  in immunocompromised Recommended contraindicated 
Use in children with chronic 
salicylate therapy 
Recommended contraindicated 
Can be administered to persons 
at high 
Risk for influenza-related 
complications 
Recommended not recommended 
Use for family members or 
close contacts of 
immunosuppressed persons not 
Requiring a protected 
environment 
Yes yes 
Use for family members or 
close contacts of severely 
immunosupressed persons 
Requiring a protected 
environment 
Preferred yes 
Use during pregnancy Recommended contraindicated 
Anaphylactic allergy to eggs Contraindicated contraindicated 
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The trivalent inactivated vaccine (TIV) against influenza is recommended for mass 
vaccination programs, while live attenuated vaccine (LAIV) may be given only to 
healthy people aged 5-49 years and it is not licensed in all countries. Main differences 
between vaccines (TIV and LAIV) are presented in table 2 [6]. 
Influenza vaccination of  travellers provides [6-9]: 
• a chance to avoid the disease and its complications (because of a short 
incubation period of the disease (1-3 days), exposure during travel can disrupt a 
business trip or vacation); 
• a chance to reduce transfer (introducing) the disease to home country, 
• a chance to reduce the risk of its transfer to the destination country, 
• a chance to limit spreading the disease worldwide, 
• a chance to reduce the risk of antigenic shift between seasonal influenza virus 
and avian influenza virus. 
It has been proved that this vaccination is not only cost-effective but also cost-
saving [10]. 
INFLUENZA OUTBREAKS ON SHIPS 
For many years cruise ships have been known for outbreaks of gastrointestinal 
diseases, but more recently respiratory tract infections, including influenza, have been 
added to a list of diseases affecting sea travellers. Close contact with high transmission 
has been documented on cruise ships. Examples of influenza outbreaks there are 
described below. 
In  April 1984, a large outbreak of influenza-like and diarrheal illness took place on 
a ship cruising to ports in southern Europe and northern Africa. Laboratory tests 
revealed that the outbreak was caused by multiple pathogens, including influenza B 
virus infection (confirmed in 14 cases) and influenza A virus infection (confirmed in 4 
cases). A cohort study of 418 passengers was made by postal questionnaire, 391 
returned interviews, and among them 86% reported they had been affected [11]. 
An outbreak of influenza A (H3N2) occurred aboard a US Navy ship in February  
although 95% of the crew had been appropriately vaccinated. Virus isolated from ill 
crew members was antigenically distinct from the vaccination strain. With the attack 
rate of 42% (232/548 of crew members became ill), this outbreak demonstrates the 
potential for rapid spread of influenza in a confined population and the impact 
subsequent illness may have upon the workplace. Ill members of the ship missed 106 
working days, additional 8 work days were lost by probable cases; one patient must 
have been evacuated by helicopter because of a severe chest pain as a result of infection. 
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After influenza A was identified in the crew, amantadine, 100 mg twice a day for 5 days 
was offered to all unvaccinated persons (until the outbreak subsided) and those in the 
first days of illness. A total of 59 persons chose to take the antiviral drug, 49 for therapy 
and 10 for prophylaxis. A total of 28 unvaccinated crew members were onboard, 
11 (61%) of 18 unvaccinated persons who did not take amantadine met the criteria for 
influenza, but none of 10 unvaccinated persons who took amantadine prophylaxis had 
influenza-like symptoms. This outbreak demonstrates the potential for rapid spread of 
influenza A through a confined population despite appropriate vaccination (since 1954 
annual immunization  program is realized ion US Navy). This outbreak also 
demonstrates the role of stockpiling of antiviral drugs on ships – which should be used 
in case of outbreak [12]. 
In 1997, influenza-like disease was spread among passengers on North American 
cruises. There had been reviewed 1 ship medical records from 3 cruises from mid-
August till late September.  The outbreak probably began among Australian passengers 
on cruise 1 (31 August-10 September). During cruise 2 (11-20 September), 17% of 
1284 passengers reported symptoms of acute respiratory infection (ARI), among them 
77% were aged > 65 years, and 26% had other identified risk factors for respiratory 
complications. An influenza strain not previously identified in North America, was 
isolated. Epidemiological investigations resulted in conclusion that and “off-season” 
influenza outbreak occurred among international travellers and crew on a board of this 
cruise ship. This outbreak proved that summertime influenza outbreaks among 
passengers and crew members on cruise ships traveling in large groups can pose a risk 
for exposure to influenza viruses, even when the group is traveling in regions where 
influenza is not in seasonal circulation [13].  
In June-August 1998, CDC and Health Canada began investigating reports of 
febrile respiratory illness and associated pneumonia among summer land and sea 
travelers to Alaska and the Yukon Territory. Epidemiological and laboratory evidence 
has implicated influenza A virus as the etiologic agent of the outbreak. Prospective 
surveillance and retrospective case-finding have identified 5361 cases of ARI , among 
them 35% cases in tourists and tourism workers, and additional 3,2% cases were 
confirmed radiographically as pneumonia. The median age of all persons with ARI was 
60 (range 1-91 years).  Most cases of ARI were observed among smaller groups of 
tourists sharing transportation and accommodation on overland tours, and among 
passengers and crew members on cruise ships. Several cruises lines have initiated active 
surveillance for respiratory illness, organized vaccination campaigns for crew members 
and acquired stocks of influenza antiviral medications [14-16]. 
During June and July 2000, an outbreak of respiratory illness occurred on the m/s 
Rotterdam during a 12-day Baltic cruise from the United Kingdom to Germany via 
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Russia. On the board there were 1311 passengers, primaly from USA, 506 crew 
members from many countries. Results of rapid test were negative for influenza viruses, 
but immunofluorescence staining and viral culture results implicated influenza B 
infection as a cause of the outbreak.  
A total of 64 (13%) crew members and 54 (4%) passengers were identified with 
ARI during the cruise. The median age of ill crew members was 32 years and of 
passengers 69 years. By cross-referencing crew duties, cabin locations of ill crew 
members and passengers, and dates of illness, medical staff identified the potential 
index case-patient as a 78-year old US passenger who boarded the ship ill (with 
symptoms of acute respiratory infection) in London [17,18]. 
In September 2000, an outbreak of influenza-like illness was reported on a cruise 
ship between Sydney and Noumea with 1100 passengers and 400 crew on board. The 
cruise coincidented with the peak influenza period in Sydney. Laboratory testing of 
passengers and crew indicated that both influenza A and B viruses had been identified 
on the ship. Morbidity was high with 40 passengers hospitalized, two of them died. 
According to a questionnaire set to passengers 3 weeks after a cruise, 37% of them 
reported suffering from an influenza-like illness (cough, fever, myalgia), 63% had seen 
a doctor for the illness related to a cruise. One third of passengers reported a vaccination 
against influenza in 2000, but neither the morbidity nor hospitality among them was 
different from unvaccinated persons [19]. Early suspicion of a potential influenza 
outbreak among crew members and rapid implementation of a respiratory illness control 
protocol probably limited the size of the outbreak. 
GUIDELINES FOR THE PREVENTION AND CONTROL 
OF INFLUENZA-LIKE ILLNESS AMONG PASSENGERS AND CREWS 
ON CRUISE    SHIPS (CDC, 1999) 
Medical staff of cruise should routinely be educated about clinical, diagnostic and 
treatment aspects of repiratory illnesses,  their surveillance, prevention, control, with 
particular focus on influenza and pneumonia [20]. 
Key elements of the protocol which may be used for prevention and control of 
influenza outbreak on ships should include [20]: 
1. implementation of an active and passive surveillance using standard case 
definition; 
2. use of targeted rapid influenza diagnostic testing and viral cultures to confirm 
cases of influenza virus infection; 
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3. isolation of crew members meeting the ARI case definition or those with 
confirmed influenza; 
4. use of antiviral agents for treatment and, if indicated, for prophylaxis (table 3); 
5. monitoring the interventions results. 
Both passengers and crew members can serve as potential reservoirs of influenza 
infection.  Vaccination against influenza should be strongly recommended to all 
travellers, especially at the age > 65 years and other risk factors for influenza 
complications.  Cruise lines should attempt to achieve at least 80% vaccination rate 
among crew members on each ship each year. Annual vaccination against influenza 
should be done among military services, including crew members of the navy. 
Including  of  antiviral in the list of drugs in the ship’s medicine chest is 
recommended, but it should be underlined that nowadays the adamantanes are not drugs 
recommended for treatment and prophylaxis of seasonal influenza because more than 
90% currently circulating strains are resistant to this group of drugs (including 
amantadine and rimantadine) [8]. Modern antivirals belong to a group of neuraminidase 
inhibitors (zanamivir and oseltamivir), should be given for treatment. But therapy 
should be started not longer than 36-48 hours after the onset of symptoms (table 3) [8].  
Table. 3. Antiviral drugs (neuraminidase inhibitors) in prophylaxis and treatment of 
influenza [6]. 
 Oseltamivir zanamivir 
Licensed for treatment 
of seasonal influenza 
Yes yes 
Licensed for prophylaxis 
of seasonal influenza 
Yes yes 
Route of administration Oral inhalation 
Age limits allowed for individuals > 1 
year 
allowed for individuals > 
5 years 
 Duration of treatment 5 days 5 days 
Duration of contact 
prophylaxis 
10 days 10 days 
Doses for treatment in children dose varies by 
child’s weight 
In adults 2x75 mg 
2x 2 inhalations 
Doses for prophylaxis in children dose varies by 
child’s weight 
In adults 1x75 mg 
1x2 inhalations 
Bioavaibility high (80%) low (10%) 
Special comments special awareness in 
teenagers 
(possible behavioral and 
psychiatric changes) 







Influenza may be a health problem among travellers, including see travellers. 
Vaccination against this disease should be more popular in this group of people [20]. 
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